RxSight (RXST)

• Market cap: $1.19B
• 1 day: -2.41%
• 5 days: -7.64%
• 1 month: -4.42%
• 3 months: -34.30%
• 6 months: -44.85%
• Year to date: -14.33%
• 1 year: -46.15%
• 5 years: 85.00%
• 10 years: 85.00%
• Sector: Healthcare
• Industry: Ophthalmic Goods

About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Employees: 374

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,042% more call options, than puts

Call options by funds: $19.8M | Put options by funds: $1.73M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

36% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 61

1.62% more ownership

Funds ownership: 86.01% [Q3] → 87.63% (+1.62%) [Q4]

2% less first-time investments, than exits

New positions opened: 40 | Existing positions closed: 41

2% less funds holding

Funds holding: 213 [Q3] → 209 (-4) [Q4]

28% less capital invested

Capital invested by funds: $1.69B [Q3] → $1.21B (-$473M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 18% upside
• Avg. target: $48 63% upside
• High target: $66 123% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Wells Fargo Larry Biegelsen 66% 1-year accuracy 31 / 47 met price target	35% upside $40	Equal-Weight Maintained	13 Jan 2025
Stifel Thomas Stephan 44% 1-year accuracy 8 / 18 met price target	18% upside $35	Hold Maintained	13 Jan 2025
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target	123% upside $66	Buy Reiterated	13 Jan 2025
UBS Danielle Antalffy 69% 1-year accuracy 9 / 13 met price target	76% upside $52	Buy Initiated	6 Dec 2024